Meta-analyses of the reduction in HbA1c with SGLT2 inhibitors in type 2 diabetes have consistently noted reductions of about 0.5 to 1% (6–11 mmol/mol) from a baseline of around 8% (64 mmol/mol) [10–12]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.